Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 17;58(12):1867.
doi: 10.3390/medicina58121867.

Meta-Analysis of Survival Effects of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)

Soo Young Jeong  1   2 , Kyung-Jun Lee  2 , Jieum Cha  1 , So Yoon Park  1 , Hyeong Su Kim  2   3 , Jung Han Kim  3 , Jae-Jun Lee  2   4 , Namhyeok Kim  2 , Sung Taek Park  1   2
Affiliations
Review

Meta-Analysis of Survival Effects of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)

Soo Young Jeong et al. Medicina (Kaunas). .

Abstract

Background and Objectives: Identification and targeting of membrane proteins in tumor cells is one of the key steps in the development of cancer drugs. The receptor tyrosine kinase-like orphan receptor (ROR) type 1 is a type-I transmembrane protein expressed in various cancer tissues, which is in contrast to its limited expression in normal tissues. These characteristics make ROR1 a candidate target for cancer treatment. This study aimed to identify the prognostic value of ROR1 expression in cancers. Materials and Methods: We conducted a comprehensive systematic search of electronic databases (PubMed) from their inception to September 2021. The included studies assessed the effect of ROR1 on overall survival (OS) and progression-free survival (PFS). Hazard ratios (HR) from collected data were pooled in a meta-analysis using Revman version 5.4 with generic inverse-variance and random effects modeling. Results: A total of fourteen studies were included in the final analysis. ROR1 was associated with worse OS (HR 1.95, 95% confidence interval (CI) 1.50−2.54; p < 0.001) with heterogeneity. The association between poor OS and ROR1 expression was high in endometrial cancer, followed by ovarian cancer, and diffuse large B cell lymphoma. In addition, ROR1 was associated with poor PFS (HR 1.84, 95% CI 1.60−2.10; p < 0.001), but heterogeneity was not statistically significant. In subgroup analysis, high ROR1 expression showed a significantly higher rate of advanced stage or lymph node metastasis. Conclusions: This meta-analysis provides evidence that ROR1 expression is associated with adverse outcome in cancer survival. This result highlights ROR1 as a target for developmental therapeutics in cancers.

Keywords: ROR1; cancer; meta-analysis; receptor tyrosine kinase-like orphan receptor 1.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart for the receptor tyrosine kinase-like orphan receptor 1 (ROR1) data selection.
Figure 2
Figure 2
Funnel plot for (A) overall survival, and (B) progression-free survival, according to ROR1 expression. Dots(o) represent individual studies.
Figure 3
Figure 3
Forest plot showing hazard ratios for (A) overall survival, and (B) progression-free survival, according to ROR1 expression.
Figure 4
Figure 4
Forest plot of odds ratio for (A) advanced stages (I/II vs. III/IV) and (B) lymph node metastasis.
See this image and copyright information in PMC

References

    1. Wu W., Hu W., Kavanagh J.J. Proteomics in cancer research. Int. J. Gynecol. Cancer. 2002;12:409–423. doi: 10.1136/ijgc-00009577-200209000-00001. - DOI - PubMed
    1. Liu Y.M., Lian F., Zhou X.F., Chen W.C., Liu H.K., Yao W., Fan W.Z., Li J.P., Chen J., Wang Y. Safety and efficacy of transarterial embolization combined with octreotide LAR on reducing tumor burden for neuroendocrine tumor liver metastasis. Zhonghua Yi Xue Za Zhi. 2019;99:1142–1146. - PubMed
    1. Esparis-Ogando A., Montero J.C., Arribas J., Ocana A., Pandiella A. Targeting the EGF/HER Ligand-Receptor System in Cancer. Curr. Pharm. Des. 2016;22:5887–5898. doi: 10.2174/1381612822666160715132233. - DOI - PubMed
    1. Clevers H., Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012;149:1192–1205. doi: 10.1016/j.cell.2012.05.012. - DOI - PubMed
    1. Bourroul G.M., Fragoso H.J., Gomes J.W., Bourroul V.S., Oshima C.T., Gomes T.S., Saba G.T., Palma R.T., Waisberg J. The destruction complex of beta-catenin in colorectal carcinoma and colonic adenoma. Einstein. 2016;14:135–142. doi: 10.1590/S1679-45082016AO3678. - DOI - PMC - PubMed

Substances